Perspective Therapeutics receives FDA Fast Track Designation for PSV359 in solitary fibrous tumors

Perspective Therapeutics, Inc. (NYSE American: CATX) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for the development of PSV359. This designation is for adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein-positive solitary fibrous tumors.